Not all treatment-resistant RA is actually treatment-resistant. A new three-step diagnostic algorithm presented at PRD 2026 urges rheumatologists to phenotype patients first — separating inflammatory from noninflammatory causes — before escalating therapy. Up to half of difficult-to-treat RA cases may be driven by pain sensitization or comorbidities, not active inflammation.
Not all "difficult-to-treat" RA is truly refractory — and that distinction matters.
A new diagnostic algorithm presented at Perspectives in Rheumatic Diseases (PRD) 2026 is pushing rheumatologists to rethink how they approach difficult-to-treat rheumatoid arthritis (D2T RA). Developed by Dr. Bryant R. England of the University of Nebraska Medical Center, the three-step decision tree centers on one core principle: phenotype before you prescribe. Rather than defaulting to more aggressive anti-inflammatory therapy, clinicians are urged to first determine whether a patient's symptoms are actually driven by inflammation — or by something else entirely.
The algorithm identifies three key phenotypes: chronic pain/pain sensitization, multimorbidity, and persistent inflammatory refractory RA (PIRRA). England estimates that noninflammatory causes account for roughly half of D2T RA cases, meaning that escalating DMARDs in those patients may do more harm than good. The workup hinges on swollen joint counts and systemic inflammatory biomarkers — not tender joints alone, which can be misleading.
Key Takeaways:
Why it matters: Many D2T RA patients are caught in a cycle of escalating medications that don't address the real source of their symptoms. This algorithm offers a practical, structured way to break that cycle — and potentially improve outcomes without adding drug burden.
